RCT: No benefit from second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis
18 Apr, 2021 | 21:21h | UTCSecond intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial – The Lancet Neurology (link to abstract – $ for full-text)